ArticlePloS one2021
Variability in digestive and respiratory tract Ace2 expression is associated with the microbiome.
Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 43 citations in OpenAlex.
- Peptide IRW upregulates ACE2 in spontaneously hypertensive rats via dopamine/D1R signaling pathway.Journal of advanced research · 2026Article
- Fecal ACE and ACE2 Activities Reflect Intestinal Shedding and Microbiota Modulation of Renin-Angiotensin System.Biology · 2026Article
- Human microbiome in post-acute COVID-19 syndrome (PACS).Current research in microbial sciences · 2025Article
- Familial clustering of dysbiotic oral and fecal microbiomes in juvenile dermatomyositis.Scientific reports · 2024Observational
- Induction of Superior Systemic and Mucosal Protective Immunity to SARS-CoV-2 by Nasal Administration of a VSV-ΔG-Spike Vaccine.Vaccines · 2024Article
- Microbiota and Immunity during Respiratory Infections: Lung and Gut Affair.International journal of molecular sciences · 2024Review
- Gastrointestinal symptoms in COVID-19 and disease severity: a Japanese registry-based retrospective cohort study.Journal of gastroenterology · 2024Article
- What we need to know about the germ-free animal models.AIMS microbiology · 2024Review
- Gut Microbiota Dysbiosis in COVID-19: Modulation and Approaches for Prevention and Therapy.International journal of molecular sciences · 2023Review
- Gut microbiota in COVID-19: key microbial changes, potential mechanisms and clinical applications.Nature reviews. Gastroenterology & hepatology · 2023Review
- Changes of gut microbiota under different nutritional methods in elderly patients with severe COVID-19 and their relationship with prognosis.Frontiers in immunology · 2023Article
- Mechanism and potential treatments for gastrointestinal dysfunction in patients with COVID-19.World journal of gastroenterology · 2022Review
- Gut and airway microbiota and their role in COVID-19 infection and pathogenesis: a scoping review.Infection · 2022Article
- Oral dysbiosis and its linkage with SARS-CoV-2 infection.Microbiological research · 2022Article
- Altered gut microbiota patterns in COVID-19: Markers for inflammation and disease severity.World journal of gastroenterology · 2022Review
- Tripartite communication in COVID-19 infection: SARS-CoV-2 pathogenesis, gut microbiota and ACE2.Future virology · 2022Article
- Protection by metformin against severe Covid-19: An in-depth mechanistic analysis.Diabetes & metabolism · 2022Review
- Nasopharyngeal Microbiota as an early severity biomarker in COVID-19 hospitalised patients.The Journal of infection · 2022Article
- Roles of the gut microbiota in severe SARS-CoV-2 infection.Cytokine & growth factor reviews · 2022Review
- Phage therapy in the Covid-19 era: Advantages over antibiotics.Current research in microbial sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
COVID-19 (coronavirus disease 2019) patients exhibiting gastrointestinal symptoms are reported to have worse prognosis. Ace2 (angiotensin-converting enzyme 2), the gene encoding the host protein to which SARS-CoV-2 spike proteins bind, is expressed in the gut and therefore may be a target for preventing or reducing severity of COVID-19. Here we test the hypothesis that Ace2 expression in the gastrointestinal and respiratory tracts is modulated by the microbiome. We used quantitative PCR to profile Ace2 expression in germ-free mice, conventional raised specific pathogen-free mice, and gnotobiotic mice colonized with different microbiota. Intestinal Ace2 expression levels were significantly higher in germ-free mice compared to conventional mice. A similar trend was observed in the respiratory tract. Intriguingly, microbiota depletion via antibiotics partially recapitulated the germ-free phenotype, suggesting potential for microbiome-mediated regulation of Ace2 expression. Variability in intestinal Ace2 expression was observed in gnotobiotic mice colonized with different microbiota, partially attributable to differences in microbiome-encoded proteases and peptidases. Together, these data suggest that the microbiome may be one modifiable factor determining COVID-19 infection risk and disease severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.